Qulipta (atogepant) is not a controlled substance. The DEA assigns it no schedule under the Controlled Substances Act, meaning it carries no special restrictions on prescribing, refills, or how pharmacies handle it. This puts it in a different category from several older migraine medications that do require controlled substance oversight.
Why Qulipta Isn’t Scheduled
The DEA schedules drugs based on their potential for abuse and physical dependence. Before Qulipta’s FDA approval in 2021, the agency reviewed receptor binding studies, animal data, and adverse event reports from clinical trials. The conclusion: atogepant does not present a signal for abuse and does not require scheduling.
In the clinical trial program, no participants reported euphoria, drug tolerance, or withdrawal symptoms. When patients stopped taking the medication, no new side effects emerged afterward, suggesting there’s no rebound effect. The most common side effects that could theoretically overlap with abuse-related concerns were dizziness and drowsiness, but these occurred in isolation and never alongside euphoria or drug-seeking behavior. Across all trial groups, abuse-related adverse events ranged from 3.3% to 4.8% in people taking Qulipta compared to 1.5% on placebo, and none of these events indicated actual misuse.
How It Works in the Body
Qulipta belongs to a class of drugs called gepants. These are small molecules that block a protein called CGRP from binding to its receptor. CGRP plays a central role in triggering migraine attacks: it activates pain-signaling nerve fibers around the brain and in the membranes surrounding it. By interrupting that process early, Qulipta prevents the migraine cascade from getting started.
This mechanism is fundamentally different from controlled migraine drugs, which tend to work on the brain’s reward or sedation pathways. Qulipta doesn’t interact with dopamine, opioid, or sedative systems. It targets pain signaling specific to migraine, which is a key reason it has no abuse potential.
Migraine Drugs That Are Controlled
Several other migraine treatments do carry DEA scheduling, which is useful context for understanding where Qulipta fits:
- Butalbital combinations (such as Fiorinal) are Schedule III. These contain a barbiturate, which produces sedation and carries a real risk of dependence.
- Codeine and dihydrocodeine combinations are Schedule III. These are opioid-containing pain relievers sometimes prescribed for severe migraine.
- Lasmiditan (Reyvow) is Schedule V. It’s a newer migraine-specific drug, but it produced feelings of euphoria and sedation in trials, earning it the lowest controlled substance classification.
- Dichloralphenazone (found in older formulations like Midrin) is Schedule IV due to its sedative properties.
Qulipta’s non-controlled status reflects genuine pharmacological differences from these drugs, not just a regulatory technicality.
What This Means for Prescriptions and Refills
Because Qulipta is not controlled, your prescription process is simpler in several practical ways. Your doctor can call in or electronically send the prescription without the additional verification steps required for controlled substances. Refills are more straightforward: a non-controlled prescription is typically valid for one year from the date it’s written and can be refilled as many times as your prescriber authorizes within that window. If your prescription runs out of refills and your pharmacist can’t reach your doctor right away, they may be able to dispense a short emergency supply (often up to 14 days) to prevent a gap in your preventive treatment.
By contrast, controlled substances often require a new prescription for each fill, limit the number of refills, or mandate that prescriptions be sent electronically through specific monitoring systems.
Common Side Effects
The most frequently reported side effects in clinical trials were nausea, constipation, and fatigue or drowsiness. At the 60 mg dose, nausea affected 9% of participants (compared to 3% on placebo), constipation affected 8% (versus 2%), and fatigue or drowsiness affected 5% (versus 4%). At lower doses, these rates were slightly lower. None of these side effects are associated with addiction or misuse.
Qulipta is approved for preventive treatment of migraine in adults, meaning you take it daily to reduce how often migraines occur rather than using it to stop a migraine once it starts. It’s available in 10 mg, 30 mg, and 60 mg tablets.